congressional Inquiry Launched into Alleged Vaccine Delay

The U.S. House judiciary Committee has formally requested information from Pfizer Inc (PFE) regarding claims made by a former executive. These claims suggest that the company intentionally postponed the release of clinical trial data for its COVID-19 vaccine to potentially sway the outcome of the 2020 U.S. presidential election. The inquiry centers around statements attributed to Philip Dormitzer,who previously served as Pfizer’s global head of vaccine research during the Trump management.

the Allegations: A Timeline of Suspicion

The core of the issue revolves around the timing of Pfizer’s announcement of its vaccine’s successful trial results. The announcement, made on November 9, 2020, came shortly after Joe biden was declared the winner of the election. Critics have long questioned whether this timing was coincidental or strategically planned. Pfizer has consistently denied any connection between the election and the release of its data.

Though, the allegations against Dormitzer, first reported by The Wall Street Journal in March, have reignited the controversy. According to the Judiciary committee, Dormitzer allegedly expressed concerns to colleagues at GSK PLC (GSK), where he moved in 2021, about potential scrutiny from a hypothetical Trump re-election. The committee’s letter to Pfizer CEO Albert bourla states that GSK informed them Dormitzer requested a transfer to Canada in November 2024, fearing repercussions from a new Trump administration.

Dr. Dormitzer has assured GSK that the CEO of Pfizer knew nothing about the delay.

House Judiciary Committee Press Release

Furthermore, GSK reportedly informed the committee that Dormitzer claimed that senior figures within Pfizer’s research and growth department deliberately slowed down the clinical trials to prevent results from being finalized before the election. This claim, if substantiated, could have significant ramifications for public trust in pharmaceutical companies and the integrity of scientific research.

Pfizer’s Response and Dormitzer’s Defense

Pfizer maintains that the development of its COVID-19 vaccine was driven purely by scientific principles and guided by the U.S. food and Drug Administration (FDA). Amy rose,a Pfizer spokesperson,stated that the company received the committee’s letter and will respond directly,dismissing the allegations as “untrue and fabricated.”

Dormitzer himself has refuted the allegations, telling Reuters in March that he and his Pfizer colleagues “did everything to get the FDA emergency permit at the earliest possible time” and that any other interpretation of his comments would be “wrong.”

Broader implications and the Ongoing Inquiry

The House Judiciary Committee has also sent a similar letter to Dormitzer, seeking further information and requesting an interview.GSK has declined to comment on the matter. The Wall Street Journal further reported that GSK had reported Dormitzer’s alleged statements to the New york State Attorney General’s office, prompting the House Committee’s investigation.

This investigation arrives at a time when public trust in institutions, including pharmaceutical companies, is already fragile. According to a recent study by the Pew Research Center, only 35% of Americans have a great deal of confidence in medical scientists to act in the public’s best interest. Allegations of political interference in scientific research could further erode this trust, potentially impacting public health initiatives and vaccine uptake.

The outcome of this investigation could have far-reaching consequences, not only for Pfizer and its executives but also for the broader pharmaceutical industry and the public’s perception of scientific integrity. Archynetys will continue to follow this developing story and provide updates as thay become available.